Affordable Access

Incidence and clinical characteristics of posttransplant lymphoproliferative disorders: report from a single center.

Authors
  • Muti, G
  • De Gasperi, A
  • Cantoni, S
  • Oreste, P
  • Gini, G
  • Civati, G
  • Busnach, G
  • Brando, B
  • Frigerio, M
  • Mangiavacchi, M
  • Alberti, A
  • Decarus, L
  • Rondinara, G
  • De Giuli, E
  • Morra, E
Type
Published Article
Journal
Transplant international : official journal of the European Society for Organ Transplantation
Publication Date
Jan 01, 2000
Volume
13 Suppl 1
Identifiers
PMID: 11112038
Source
Medline
License
Unknown

Abstract

In the period 1973-1998, among 2139 allograft recipients treated with standard immunosuppression, posttransplant lymphoproliferative disorders (PTLD) developed in 19 patients (0.9%): one plasmacytic hyperplasia, two polymorphic PTLD, one myeloma, and 15 lymphomas. PTLD developed 1 year after transplantation (tx) in 14 patients. Five patients were diagnosed at autopsy, 2 were lost to follow up, 3 died before therapy could be instituted, and 1 patient has just started chemotherapy. Of the 8 evaluable patients, 2 received acyclovir and are alive in complete remission (CR) and 6 received chemotherapy +/- surgery. Of these 6, 4 died of lymphoma and/or infection, 1 died of unrelated causes in CR, and 1 is alive in CR. PTLD is a severe complication of tx, usually running an aggressive course which may preclude prompt diagnosis and treatment. Nevertheless, therapy is feasible and must be tailored on the histologic subtype. Seventy-four percent of patients were diagnosed with late-onset PTLD stressing the need for long-term follow up.

Report this publication

Statistics

Seen <100 times